Patents by Inventor Ekta Seth Chhabra
Ekta Seth Chhabra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240083975Abstract: The present invention provides a chimeric molecule comprising a VWF protein fused to a heterologous moiety via a VWF linker. The invention provides an efficient VWF linker that can be cleaved in the presence of thrombin. The chimeric molecule can further comprise a polypeptide chain comprising a FVIII protein and a second heterologous moiety, wherein the chain comprising the VWF protein and the chain comprising the FVIII protein are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.Type: ApplicationFiled: July 25, 2023Publication date: March 14, 2024Inventors: Ekta Seth CHHABRA, John KULMAN, Tongyao LIU
-
Publication number: 20230011438Abstract: The present invention provides a VWF fragment comprising the D? domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.Type: ApplicationFiled: May 27, 2022Publication date: January 12, 2023Inventors: Ekta Seth CHHABRA, Tongyao LIU, Robert T. PETERS, Haiyan JIANG
-
Publication number: 20220275057Abstract: The present invention provides a chimeric protein comprising a first polypeptide which comprises a FVIII protein and a first Ig constant region or a portion thereof and a second polypeptide which comprises a VWF protein comprising the D? domain and D3 domain of VWF, a XTEN sequence having less than 288 amino acids in length, and a second Ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.Type: ApplicationFiled: November 5, 2021Publication date: September 1, 2022Inventors: Ekta Seth CHHABRA, Tongyao LIU, Robert T. PETERS, John KULMAN
-
Patent number: 11370827Abstract: The present invention provides a VWF fragment comprising the D? domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.Type: GrantFiled: January 12, 2013Date of Patent: June 28, 2022Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Ekta Seth Chhabra, Tongyao Liu, Robert T Peters, Haiyan Jiang
-
Publication number: 20220106383Abstract: The present invention provides a chimeric molecule comprising a VWF protein fused to a heterologous moiety via a VWF linker. The invention provides an efficient VWF linker that can be cleaved in the presence of thrombin. The chimeric molecule can further comprise a polypeptide chain comprising a FVIII protein and a second heterologous moiety, wherein the chain comprising the VWF protein and the chain comprising the FVIII protein are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.Type: ApplicationFiled: September 20, 2021Publication date: April 7, 2022Inventors: Ekta Seth CHHABRA, John KULMAN, Tongyao LIU
-
Publication number: 20220056108Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D? domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein.Type: ApplicationFiled: June 25, 2021Publication date: February 24, 2022Inventors: Ekta Seth CHHABRA, Tongyao LIU, Pei-yun CHANG, Robert T. PETERS, John KULMAN, Haiyan JIANG
-
Patent number: 11192936Abstract: The present invention provides a chimeric protein comprising a first polypeptide which comprises a FVIII protein and a first Ig constant region or a portion thereof and a second polypeptide which comprises a VWF protein comprising the D? domain and D3 domain of VWF, a XTEN sequence having less than 288 amino acids in length, and a second Ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.Type: GrantFiled: January 9, 2015Date of Patent: December 7, 2021Assignee: Bioverativ Therapeutics Inc.Inventors: Ekta Seth Chhabra, Tongyao Liu, Robert T. Peters, John Kulman
-
Patent number: 11091534Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D? domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein.Type: GrantFiled: October 8, 2018Date of Patent: August 17, 2021Assignee: Bioverativ Therapeutics Inc.Inventors: Ekta Seth Chhabra, Tongyao Liu, Pei-yun Chang, Robert T. Peters, John Kulman, Haiyan Jiang
-
Publication number: 20210238259Abstract: The present disclosure provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present disclosure further discloses methods of making and using the FIX fusion proteins.Type: ApplicationFiled: January 31, 2018Publication date: August 5, 2021Inventors: Arjan VAN DER FLIER, Zhiqian LIU, David R. LIGHT, Ekta Seth CHHABRA, Tongyao LIU, Robert T. PETERS, John KULMAN, Ayman ISMAIL
-
Publication number: 20210032616Abstract: The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.Type: ApplicationFiled: July 6, 2020Publication date: February 4, 2021Inventors: Zhiqian LIU, Arjan VAN DER FLIER, David R. LIGHT, Ekta Seth CHHABRA, Tongyao LIU, Robert T. PETERS, John KULMAN, Ayman ISMAIL
-
Patent number: 10745680Abstract: The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.Type: GrantFiled: August 3, 2016Date of Patent: August 18, 2020Assignee: Bioverativ Therapeutics Inc.Inventors: Zhiqian Liu, Arjan Van Der Flier, David R. Light, Ekta Seth Chhabra, Tongyao Liu, Robert T. Peters, John Kulman, Ayman Ismail
-
Patent number: 10548953Abstract: The present invention provides chimeric proteins comprising a Factor VIII (FVIII) polypeptide and XTEN polypeptides. The FVIII polypeptide can have a reduced affinity for von Willebrand Factor (VWF). XTEN polypeptides of appropriate sizes are inserted into the FVIII polypeptide at particular locations in order to extend the half-life of the FVIII polypeptide. The invention also includes nucleotides, vectors, host cells, and methods of using the chimeric proteins, e.g., to treat bleeding diseases and disorders.Type: GrantFiled: August 14, 2014Date of Patent: February 4, 2020Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Tongyao Liu, Pei-Yun Chang, John Kulman, Volker Schellenberger, Haiyan Jiang, Robert T. Peters, Ekta Seth Chhabra
-
Publication number: 20190375822Abstract: The present disclosure provides a method of treating hemophilia A in a human subject in need thereof comprising administering to the subject a chimeric polypeptide comprising (i) a factor VIII (FVIII) protein and (ii) a von Willebrand factor (VWF) fragment comprising a D? domain of VWF and a D3 domain of VWF at a dosing interval.Type: ApplicationFiled: May 17, 2019Publication date: December 12, 2019Inventors: Ekta SETH CHHABRA, Alison INNES, Dan RUDIN, Kara RICE, Nancy WONG, Suresh KATRAGADDA
-
Publication number: 20190169267Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D? domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein.Type: ApplicationFiled: October 8, 2018Publication date: June 6, 2019Applicant: Bioverativ Therapeutics Inc.Inventors: Ekta Seth CHHABRA, Tongyao LIU, Pei-yun CHANG, Robert T. PETERS, John KULMAN
-
Publication number: 20180355341Abstract: The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.Type: ApplicationFiled: August 3, 2016Publication date: December 13, 2018Applicant: Bioverativ Therapeutics Inc.Inventors: Zhiqian LIU, Ajan VAN DER FLIER, David R. LIGHT, Ekta Seth CHHABRA, Tongyao LIU, Robert T. PETERS, John KULMAN, Ayman ISMAIL
-
Patent number: 10138291Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D? domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein.Type: GrantFiled: July 10, 2013Date of Patent: November 27, 2018Assignee: Bioverativ Therapeutics Inc.Inventors: Ekta Seth Chhabra, Tongyao Liu, Pei-yun Chang, Robert T. Peters, John Kulman
-
Publication number: 20170073393Abstract: The present invention provides a chimeric protein comprising a first polypeptide which comprises a FVIII protein and a first Ig constant region or a portion thereof and a second polypeptide which comprises a VWF protein comprising the D? domain and D3 domain of VWF, a XTEN sequence having less than 288 amino acids in length, and a second Ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.Type: ApplicationFiled: January 9, 2015Publication date: March 16, 2017Applicant: Biogen MA Inc.Inventors: Ekta Seth CHHABRA, Tongyao LIU
-
Publication number: 20160251408Abstract: The present invention provides a chimeric molecule comprising a VWF protein fused to a heterologous moiety via a VWF linker. The invention provides an efficient VWF linker that can be cleaved in the presence of thrombin. The chimeric molecule can further comprise a polypeptide chain comprising a FVIII protein and a second heterologous moiety, wherein the chain comprising the VWF protein and the chain comprising the FVIII protein are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.Type: ApplicationFiled: June 27, 2014Publication date: September 1, 2016Applicant: Biogen MA Inc.Inventors: Ekta Seth CHHABRA, John KULMAN, Tongyao LIU
-
Publication number: 20160229903Abstract: The present invention provides a chimeric molecule comprising a VWF protein fused to a heterologous moiety via a VWF linker. The invention provides an efficient VWF linker that can be cleaved in the presence of thrombin. The chimeric molecule can further comprise a polypeptide chain comprising a FVIII protein and a second heterologous moiety, wherein the chain comprising the VWF protein and the chain comprising the FVIII protein are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.Type: ApplicationFiled: June 27, 2014Publication date: August 11, 2016Applicant: Biogen MA Inc.Inventors: Ekta Seth CHHABRA, John KULMAN, Tongyao LIU
-
Publication number: 20160199454Abstract: The present invention provides chimeric proteins comprising a Factor VIII (FVIII) polypeptide and XTEN polypeptides. The FVIII polypeptide can have a reduced affinity for von Willebrand Factor (VWF). XTEN polypeptides of appropriate sizes are inserted into the FVIII polypeptide at particular locations in order to extend the half-life of the FVIII polypeptide. The invention also includes nucleotides, vectors, host cells, and methods of using the chimeric proteins, e.g., to treat bleeding diseases and disorders.Type: ApplicationFiled: August 14, 2014Publication date: July 14, 2016Applicants: Biogen MA Inc., Amunix Operating Inc.Inventors: Tongyao LIU, Pei-Yun CHANG, John KULMAN, Volker SCHELLENBERGER, Haiyan JIANG, Robert T. PETERS, Ekta Seth CHHABRA